Alebund Pharmaceuticals announced significant progress in H1 2026, including completion of patient enrollment for its AP301 Phase III trial and acceptance of its New Drug Application for AP301 by China's NMPA. The company saw a 761.2% revenue increase to RMB104.2 million, driven by licensing revenue and Mircera® sales, while losses narrowed by 22.5%. Alebund is advancing multiple clinical trials and expanding manufacturing and commercialization capabilities, aiming for regulatory approvals in China and the US by 2027.
DaVita has launched a value-based care partnership with Humana to provide coordinated care for over 10,000 Medicare Advantage members with chronic kidney disease stages 3B–5. The program focuses on early intervention to slow disease progression, redu...
AllianceBernstein Global High Income Fund, Inc. released its July 31, 2026 portfolio update, showing total net assets of $970.77 million and a net asset value of $11.26 per share. The fund holds a diversified portfolio of 1,190 fixed-income securitie...
